Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

 

CEO: Gordon Sanghera

Website: www.nanoporetech.com

Ticker symbol: Privately held

Headquarters: Oxford, UK

Number of employees: 250+

In Nature this week: nanopore sequencing and assembly human genome, method to reduce CRISPR off-target effects, and more.

Such Long Sequences

Researchers have used a portable nanopore sequencer to sequence and assemble a human reference genome.

The researchers plan to develop a clinical test to monitor CML patients in remission for the BCR-ABL1 rearrangement. 

In Nucleic Acids Research this week: tool to identify bacterial plasmid sequences, long-read sequencing of Saccharomyces cerevisiae strain, and more.

More than a third of NGS users plan to purchase a new sequencing system within a year, according to the survey, conducted by GenomeWeb and investment bank William Blair. 

Shrink It Down

Portable DNA sequencers are being used in wider range of locations, the Economist reports.

Japanese researchers developing the method highlighted its ability to accurately and rapidly diagnose different strains of malaria in resource-limited endemic regions. 

The company said that several companies in China are installing the GridIon X5 sequencing platform for in-house and service work.

In its suit PacBio alleges that Oxford Nanopore infringes two patents it holds related to nanopore sequencing. 

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

Pages

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.